These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10947200

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
    Sasongko TH, Nagalla S, Ballas SK.
    Cochrane Database Syst Rev; 2013 Mar 28; (3):CD009191. PubMed ID: 23543572
    [Abstract] [Full Text] [Related]

  • 3. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
    Laffel LM, McGill JB, Gans DJ.
    Am J Med; 1995 Nov 28; 99(5):497-504. PubMed ID: 7485207
    [Abstract] [Full Text] [Related]

  • 4. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group.
    Viberti G, Mogensen CE, Groop LC, Pauls JF.
    JAMA; 1994 Jan 26; 271(4):275-9. PubMed ID: 8295285
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.
    Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP.
    Clin J Am Soc Nephrol; 2009 Nov 26; 4(11):1741-6. PubMed ID: 19808227
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial.
    Rodríguez-Morán M, Guerrero-Romero F.
    Clin Nephrol; 2005 Aug 26; 64(2):91-7. PubMed ID: 16114784
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.
    Mathiesen ER, Hommel E, Giese J, Parving HH.
    BMJ; 1991 Jul 13; 303(6794):81-7. PubMed ID: 1860008
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up.
    Lama G, Salsano ME, Pedulla' M, Grassia C, Ruocco G.
    Pediatr Nephrol; 1997 Dec 13; 11(6):714-8. PubMed ID: 9438650
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.
    Melis D, Parenti G, Gatti R, Casa RD, Parini R, Riva E, Burlina AB, Dionisi Vici C, Di Rocco M, Furlan F, Torcoletti M, Papadia F, Donati A, Benigno V, Andria G.
    Clin Endocrinol (Oxf); 2005 Jul 13; 63(1):19-25. PubMed ID: 15963056
    [Abstract] [Full Text] [Related]

  • 12. [The effect of captopril therapy on the degree of microalbuminuria in diabetic children and adolescents with incipient nephropathy].
    Barkai L, Soós A, Vámosi I.
    Orv Hetil; 1996 Nov 17; 137(46):2565-8. PubMed ID: 9005384
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The effects of long-term captopril treatment on the evolution of urinary albumin excretion in patients with non-insulin-dependent diabetes mellitus].
    González Castro ML, Cordero Guevara J, Sáez Fernández A, Sagredo Pérez J, Arrojo Arias E, del Saz Moreno V.
    Aten Primaria; 1997 Sep 30; 20(5):221-8. PubMed ID: 9453770
    [Abstract] [Full Text] [Related]

  • 15. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria.
    Donnelly R, Molyneaux LM, Willey KA, Yue DK.
    Am J Cardiol; 1996 Feb 22; 77(6):26B-30B. PubMed ID: 8848991
    [Abstract] [Full Text] [Related]

  • 16. Hyperfiltration and renal disease in glycogen storage disease, type I.
    Baker L, Dahlem S, Goldfarb S, Kern EF, Stanley CA, Egler J, Olshan JS, Heyman S.
    Kidney Int; 1989 Jun 22; 35(6):1345-50. PubMed ID: 2671467
    [Abstract] [Full Text] [Related]

  • 17. The effects of angiotensin-converting enzyme inhibitors on the clinical and biochemical parameters in diabetic nephropathy.
    Gültekin F, Erdoğan GH, Ozersoy U, Alagözlü H.
    Ren Fail; 1993 Jun 22; 15(5):615-22. PubMed ID: 8290708
    [Abstract] [Full Text] [Related]

  • 18. [The effect of blood pressure-reducing therapy with captopril on tubular marker excretion in type-1 diabetics with nephropathy].
    Ratzmann KP, Raskovic M, Schimke E.
    Dtsch Med Wochenschr; 1994 Jun 03; 119(22):796-800. PubMed ID: 8205941
    [Abstract] [Full Text] [Related]

  • 19. Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.
    Okechuku GO, Shoemaker LR, Dambska M, Brown LM, Mathew J, Weinstein DA.
    J Inherit Metab Dis; 2017 Sep 03; 40(5):703-708. PubMed ID: 28612263
    [Abstract] [Full Text] [Related]

  • 20. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F.
    BMJ; 1996 Sep 07; 313(7057):591-4. PubMed ID: 8806248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.